Chelation Therapy: Heavy Metal Toxicity, Cardiovascular Health, and Emerging Research

Heavy metals such as lead, mercury, and arsenic can pose significant health risks when exposure results in excessive levels in the body. The effects depend on the specific metal, the amount and duration of exposure, and individual susceptibility.

Lead exposure can affect the nervous system, contributing to cognitive impairment and neurological problems in adults, as well as learning and behavioral difficulties in children. Mercury toxicity can affect neurological and kidney function, while chronic arsenic exposure is associated with an increased risk of certain cancers, cardiovascular disease, and diabetes.

Chelation therapy uses specialized compounds called chelating agents to bind certain metals and facilitate their elimination from the body. When heavy metal toxicity is confirmed, appropriate chelation may be an important component of treatment. The choice of agent depends on the metal involved, the degree of exposure, and the patient's overall health.

Chelation Therapy and Cardiovascular Disease

Chelation therapy has also been investigated as a potential treatment for cardiovascular disease, particularly in people with a history of heart attack.

The Trial to Assess Chelation Therapy (TACT) was a large clinical trial evaluating intravenous EDTA-based chelation therapy in patients with a previous heart attack. The study reported a modest reduction in a composite measure of cardiovascular events. A subgroup analysis also suggested greater potential benefit among participants with diabetes.

These findings generated interest in the possible role of chelation in cardiovascular care. However, subsequent research has not established chelation therapy as a routine treatment for coronary artery disease, and the evidence remains mixed.

Chelation therapy is not a substitute for established cardiovascular treatments , including appropriate medications, lifestyle interventions, and other evidence-based measures. Patients considering chelation for cardiovascular health should discuss the potential benefits, limitations, and risks with a qualified healthcare professional.

What Is Chelation Therapy?

The word chelation (pronounced key-LAY-shun ) comes from the Greek word chele , meaning claw. Chelating agents bind certain metals or minerals, forming complexes that can be eliminated from the body.

Chelation therapy is an established medical treatment for specific types of heavy metal poisoning. Researchers have also investigated its potential applications in cardiovascular disease and other chronic conditions, although many of these uses remain unproven.

Different chelating agents have different properties and indications. For example:

• EDTA (ethylenediaminetetraacetic acid): Used in certain forms of metal poisoning, with the specific formulation determined by the clinical indication.
• DMSA (succimer): An oral chelating agent used for certain cases of lead poisoning.
• DMPS (2,3-dimercapto-1-propanesulfonic acid): Used in some countries and clinical settings for selected types of heavy metal poisoning.

The appropriate agent, route of administration, and treatment duration depend on the substance involved and the patient's clinical circumstances.

Some practitioners also recommend nutritional support during treatment. However, supplements such as cilantro, chlorella, and dietary fiber should not be considered substitutes for medically indicated chelation or proven treatments for heavy metal poisoning.

Nutritional Support During Chelation

Chelating agents can sometimes affect essential minerals as well as their intended targets. Depending on the agent and treatment protocol, monitoring kidney function, electrolyte levels, and essential minerals may be necessary.

Nutritional support may include selected antioxidants and other nutrients, such as N-acetylcysteine (NAC), alpha-lipoic acid (ALA), selenium, and B vitamins, when clinically appropriate.

Supplementation should be individualized rather than automatically prescribed, as excessive intake of certain nutrients can also cause harm. Laboratory monitoring and clinical assessment help guide decisions about supplementation and mineral replacement.

What Is Che-Zone Therapy?

Che-Zone Therapy is a treatment approach developed by Dr. Frank Shallenberger, MD, that combines intravenous chelation therapy with intravenous ozone therapy.

In this approach, intravenous ozone may be administered alongside other supportive treatments, including glutathione and N-acetylcysteine, before a chelation infusion.

Proponents of this approach aim to combine metal-binding therapy with additional supportive interventions. However, evidence that adding ozone therapy improves heavy metal elimination, liver function, or clinical outcomes beyond chelation alone remains limited. These potential benefits should not be considered established.

How Is Chelation Therapy Administered?

Chelation therapy may be administered orally or intravenously, depending on the chelating agent, the condition being treated, and the patient's clinical needs. Other routes may be used in specific medical settings.

Treatment duration varies:

• Intravenous chelation: Infusion time depends on the agent and protocol. Some protocols require several hours per session.
• Oral chelation: Treatment schedules vary according to the medication, indication, and monitoring requirements.

A course of treatment may involve multiple sessions, but the number and frequency should be determined by the clinical indication, laboratory findings, response to treatment, and safety considerations.

Chelation should always be conducted under appropriate medical supervision. Not every patient with a suspected heavy metal burden requires treatment, and chelation is not appropriate for every type of exposure.

Is Chelation Therapy Safe? Are There Side Effects?

Chelation therapy can be beneficial when appropriately prescribed for a confirmed indication, but it is not risk-free. Safety depends on the specific agent, dosage, administration method, kidney function, and the patient's overall health.

Potential adverse effects include:

• Nausea, vomiting, diarrhea, or other gastrointestinal symptoms
• Headache, fatigue, or fever
• Irritation or discomfort at the infusion site
• Depletion of essential minerals
• Kidney injury or other serious complications in certain circumstances

Some chelating agents can cause severe electrolyte disturbances. For example, disodium EDTA can produce dangerous reductions in blood calcium if used improperly. This formulation must not be confused with calcium disodium EDTA, which has different clinical uses and safety considerations.

Patients with impaired kidney function or other significant medical conditions require particular caution. Pregnancy and breastfeeding also require careful evaluation, and chelation is generally avoided unless there is a compelling medical indication and specialist guidance.

Before treatment, a qualified clinician should review the patient's medical history, medications, laboratory results, and potential risks. Appropriate monitoring is essential throughout treatment.

How Do I Know If I Have Elevated Heavy Metal Levels?

Symptoms associated with heavy metal exposure can be nonspecific and may overlap with many other health conditions. Testing should therefore be guided by the patient's exposure history, symptoms, and clinical assessment.

At Valley Integrative Health, evaluation may include:

• A detailed exposure and medical history
• Review of symptoms and relevant physical examination findings
• Appropriate laboratory testing, such as blood or urine testing, depending on the suspected metal and exposure
• Additional testing when clinically indicated

Hair testing may have a role in evaluating certain exposures, but its usefulness varies by metal and clinical context. Test selection and interpretation are important because not all commercial heavy metal tests have established clinical validity.

Chelation should not be initiated solely because a screening test is abnormal or because nonspecific symptoms are present. Testing results should be interpreted in the context of established reference ranges, exposure history, and the limitations of the method used.

Conditions and Research Areas

Chelation therapy has established uses for certain forms of heavy metal poisoning. Researchers have also explored its potential role in several other conditions.

Heavy metal toxicity

• Lead
• Mercury
• Arsenic
• Selected other metals, depending on the agent and clinical indication

Cardiovascular disease

• Coronary artery disease
• Atherosclerosis
• Cardiovascular risk in patients with diabetes

Neurological and other conditions under investigation

• Alzheimer's disease
• Parkinson's disease
• Multiple sclerosis
• Autism
• Age-related macular degeneration
• Rheumatoid arthritis

Research involving these conditions varies considerably in quality and scope. Inclusion on this list does not mean chelation therapy has been proven effective or is recommended for the condition. Chelation is not an established treatment for autism, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, or age-related macular degeneration.

Is Chelation Therapy FDA-Approved?

The U.S. Food and Drug Administration (FDA) has approved specific chelating medications for particular medical indications, including certain types of heavy metal poisoning. Approval applies to the individual drug and its labeled uses, not to chelation therapy as a treatment for every condition.

Chelation therapy is not FDA-approved as a general treatment for cardiovascular disease, atherosclerosis, or other chronic diseases discussed above. Its use for these purposes remains outside established standard care.

Research on Chelation Therapy

The Trial to Assess Chelation Therapy (TACT) was an important study examining EDTA-based chelation in patients with a history of heart attack. Its findings suggested a modest reduction in cardiovascular events, with a potentially greater effect in a subgroup of participants with diabetes.

However, subgroup findings require careful interpretation, and subsequent research has not established routine cardiovascular chelation as standard treatment. Further research is needed to determine whether particular patient groups may benefit and to better define the treatment's safety profile.

For heavy metal poisoning, the evidence supporting chelation depends on the specific metal, the chelating agent, and the clinical circumstances. Treatment decisions should be based on established indications and appropriate medical evaluation.

Learn More About Chelation Therapy

At Valley Integrative Health, Devin Wilson, ND, evaluates patients for potential heavy metal exposure and discusses appropriate testing and treatment options based on individual clinical needs.

Dr. Wilson has training in chelation therapy through the American College for Advancement in Medicine (ACAM) and is a Certified Chelation Therapy provider. His approach integrates naturopathic and conventional medical perspectives, with an emphasis on individualized assessment, patient education, and appropriate monitoring.

Medical disclaimer: This article is for educational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment.